Celiac Disease Industry (6MM) 2023 Epidemiology Forecasts For 6 Major Markets

News provided by

Nov 12, 2014, 07:00 ET

DALLAS, November 12, 2014 /PRNewswire/ --

RnRMarketResearch.com adds EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023 research report that provide an overview of the risk factors, comorbidities, and the global and historical trends for celiac disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast for the total prevalent cases of celiac disease segmented by sex and age (0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and =70 years), and a 10-year epidemiological forecast for the diagnosed prevalent cases of celiac disease in the 6MM.

Epidemiologists of this EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023 research report (http://www.rnrmarketresearch.com/epicast-report-celiac-disease-epidemiology-forecast-to-2023-market-report.html ) forecast that the number of total prevalent cases of celiac disease in the 6MM is expected to grow to 8.08 million cases in 2023 at a rate of 3.92% per year during the forecast period. The number of diagnosed prevalent cases in the 6MM is expected to increase by 4.61% over the next decade to 1.11 million cases in 2023. Celiac disease is an autoimmune disease that occurs in individuals who consume gluten-containing foods but are intolerant to gluten, a protein found in many grains, such as wheat, rye, and barley. In celiac disease, the body's immune system attacks and destroys the villi of the small intestine and thus interferes with nutrient absorption. Celiac disease can be difficult to diagnose because the symptoms vary between individuals and are non-specific, such as abdominal bloating and pain, diarrhea, constipation, and weight loss. Short-term malicious effects of untreated celiac disease include malnutrition, vitamin and mineral deficiency, and anemia, whereas long-term effects include bone diseases, cancers, and liver diseases. Celiac disease can arise in individuals of all ages and current epidemiological studies estimate that celiac disease affects around 1% of the population in western countries, with a range of between 0.3-2.7%.

The celiac disease epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM. The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources. The forecast and analysis is based on a thorough literature review and from primary research results. Epidemiologists maintained a consistent case-finding definition and forecasting methodology for celiac disease throughout the 6MM, thus allowing for a meaningful comparison of the total and diagnosed prevalent cases of celiac disease in these markets. The total prevalent cases of celiac disease are also segmented by sex, thus providing a detailed analysis of the patient population characteristic of celiac disease. Furthermore, epidemiologists also provided a realistic trend forecast for the total and diagnosed prevalence of celiac disease based on insights gained through the analysis of historical data. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=238787 .

List of Tables provided in this research include:

Table 1: Risk Factors for Celiac Disease
Table 2: Studies Reporting Temporal Trends for Celiac Disease and Calculated Rate of Change
Table 3: 6MM, Sources of Prevalence and Diagnosis Rates of Celiac Disease
Table 4: 6MM, Sources Not Used in Epidemiological Forecast for Celiac Disease
Table 5: 6MM, Total Prevalent Cases of Celiac Disease, Both Sexes, All Ages, N, Select Years 2013-2023
Table 6: 6MM, Age-Specific Total Prevalent Cases of Celiac Disease, Both Sexes, N (Row %), 2013
Table 7: 6MM, Sex-Specific Total Prevalent Cases of Celiac Disease, All Ages, N (Row %), 2013
Table 8: 6MM, Diagnosed Prevalent Cases of Celiac Disease, Both Sexes, All Ages, Select Years 2013-2023

List of Figures provided in EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023 research report cover:

Figure 1: 6MM, Total Prevalent Cases of Celiac Disease, Both Sexes, All Ages, N, 2013-2023
Figure 2: 6MM, Age-Specific Total Prevalent Cases of Celiac Disease, Both Sexes, N (Row %), 2013
Figure 3: 6MM, Sex-Specific Total Prevalent Cases of Celiac Disease, All Ages, 2013
Figure 4: 6MM, Age-Standardized Total Prevalence (%) of Celiac Disease, All Ages, by Sex, 2013
Figure 5: 6MM, Diagnosed Prevalent Cases of Celiac Disease, Both Sexes, All Ages, N, 2013-2023

Another research titled Celiac Disease - Pipeline Review, H1 2014 provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/celiac-disease-pipeline-review-h1-2014-market-report.html .

Explore more reports on diseases and treatments industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .

About Us:

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

Connect With Us on:

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

Twitter: https://twitter.com/RnRMR

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

RSS/Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research